The medicine Aldurazyme (Laronidase) is a polymorphic variant of the human enzyme, α-L-iduronidase, that is produced by recombinant DNA technology in a Chinese hamster ovary cell line.
Aldurazyme contains Laronidase as an active ingredient with inactive ingredients sodium chloride, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, and polysorbate 80.
Aldurazyme is used in the treatment of patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms.
Aldurazyme has been shown to improve pulmonary function and walking capacity.
The recommended dosage regimen of Aldurazyme is 0.58 mg/kg of body weight, and it should be administered once weekly as an intravenous (IV) infusion. Healthcare professionals recommend pretreatment with antipyretics and antihistamines for 60 minutes before starting the infusion.
Note: Aldurazyme must not be administered with other medicinal products in the same infusion. The compatibility of Aldurazyme in solution with other products has not been evaluated.
There is no experience with overdoses of Aldurazyme. If someone takes an overdose, consult the doctor immediately and keep the patient under observation.
Anaphylaxis and Allergic Reactions
Healthcare professionals observed Anaphylaxis and severe allergic reactions in patients during or up to 3 hours after Aldurazyme infusions. If anaphylactic or other severe allergic reactions occur, immediately discontinue the infusion of Aldurazyme and initiate appropriate medical treatment.
Acute Respiratory Complications Associated with Administration
Patients with an acute febrile or respiratory illness at the time of Aldurazyme infusion may be at greater risk for infusion reactions. One should carefully consider the patient’s clinical status before administration of Aldurazyme and consider delaying Aldurazyme infusion.
Sleep apnea is common in MPS I patients. One should consider evaluation of airway patency before initiation of treatment with Aldurazyme. Patients using supplemental oxygen or continuous positive airway pressure (CPAP) during sleep should have these treatments readily available during infusion in the event of an infusion reaction or extreme drowsiness/sleep induced by antihistamine use.
Risk of Acute Cardiorespiratory Failure
One should exercise caution when administering Aldurazyme to patients susceptible to fluid overload or patients with acute underlying respiratory illness or compromised cardiac and respiratory function for whom fluid restriction is indicated. One should make available appropriate medical support and monitoring measures during Aldurazyme infusion. Some patients may require prolonged observation times based on the patient’s individual needs.
Patients should receive antipyretics and antihistamines before infusion because of the potential for infusion reactions. If an infusion reaction occurs, regardless of pretreatment, decreasing the infusion rate, temporarily stopping the infusion, or administering additional antipyretics and antihistamines may ameliorate the symptoms.
Aldurazyme is supplied as a sterile solution in clear Type I glass 5 mL vials (2.9 mg Laronidase per 5 mL).
Aldurazyme is a medicine that contains Laronidase. Aldurazyme is used in the treatment of patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. The medicine comes in the form of vials for intravenous infusion.
The active ingredient in the medicine is Laronidase with inactive ingredients sodium chloride, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, and polysorbate 80.
Healthcare professionals recommend administering Aldurazyme intravenously, and the recommended dosage is 0.58 mg/kg of body weight, administered once weekly.
For medicine, Aldurazyme Biomarin is the innovator, and Ikris Pharma Network is an authorized partner who can help access this medicine in India for the patient through legal procedures. To know more, contact Ikris at toll-free no. 18008891064 or write at [email protected].
The Aldurazyme cost is reasonable. To authenticate this drug, you can call 18008891064 or email [email protected].
In India, you can buy Aldurazyme with the help of Ikris Pharma Network, an authorized partner of “Biomarin” for this medicine.